Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF)|
|Citation:||Clinical Endocrinology, 2009; 70(6):838-846|
|Publisher:||Blackwell Science Ltd|
|Ian Chapman, Hugh Greville, Peter R. Ebeling, Susannah J. King, Tom Kotsimbos, Patricia Nugent, Rosie Player, Duncan J. Topliss, Janet Warner and John W. Wilson|
|Abstract:||Objective: Reduced bone mineral density (BMD) and increased rates of atraumatic fracture are observed in cystic fibrosis (CF) patients, causing increasing morbidity as this population ages. The study aimed to assess the safety, tolerability and effect on BMD of intravenous zoledronate in adults with CF and osteopaenia. Design: Randomized, double-blind, placebo-controlled clinical trial. Setting: Adult CF outpatient clinics at two hospitals. Patients: Twenty-two non-transplanted CF patients aged ≥ 18 years with a bone densitometry T-score of < –1·5 at one of three sites (lumbar spine, femoral neck, distal forearm) were studied. Participants were randomized to receive either 2 mg zoledronate IV (n = 10) or normal saline (placebo, n = 12) every 3 months for 2 years (8 infusions). All participants received calcium and vitamin D supplements twice daily. Measurements: Percentage change in areal BMD from baseline. Results: Lumbar spine BMD increased from baseline more with zoledronate than placebo at 6 months (5·35 ± 0·76 vs. 1·19 ± 1·20%, P = 0·012), 12 months (6·6 ± 1·5 vs. 0·35 ± 1·55%, P = 0·011) and 24 months (6·14 ± 1·86 vs. 0·44 ± 0·10, P = 0·021). Femoral neck BMD increased more after zoledronate than placebo at 6 months (3·2 ± 1·6 vs.–1·43 ± 0·43%, P = 0·019), 12 months (4·12 ± 1·8 vs.–1·59 ± 1·4%, P = 0·024) and 24 months (4·23 ± 1·3 vs.–2·5 ± 1·41%, P = 0·0028). Forearm BMD did not change. Zoledronate was associated with flu-like and musculoskeletal side effects, particularly after the first infusion. There were no fractures in either group. Conclusion: Intravenous zoledronate was significantly more effective than placebo for increasing BMD in adults with CF and osteopaenia, but side effects limited its tolerability.|
|Keywords:||Humans; Osteoporosis; Cystic Fibrosis; Diphosphonates; Imidazoles; Placebos; Double-Blind Method; Bone Density; Adult; Female; Male; Bone Density Conservation Agents|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.